Xbrane Biopharma AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
04-22 | Transcript : Xbrane Biopharma AB - Special Call |
Sales 2024 * | 344M 31.87M 43.57M | Sales 2025 * | 680M 63.1M 86.26M | Capitalization | 309M 28.66M 39.18M |
---|---|---|---|---|---|
Net income 2024 * | -186M -17.25M -23.59M | Net income 2025 * | 104M 9.65M 13.19M | EV / Sales 2024 * | 0.82 x |
Net cash position 2024 * | 28.17M 2.61M 3.57M | Net Debt 2025 * | 116M 10.74M 14.68M | EV / Sales 2025 * | 0.62 x |
P/E ratio 2024 * |
-1.5
x | P/E ratio 2025 * |
4.22
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.26% |
Latest transcript on Xbrane Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 14-12-31 | |
Director/Board Member | 70 | 14-12-31 | |
Director/Board Member | 53 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+47.47% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |